• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Israel News

#Israel: Israel in social media

  • About
  • Support Us
  • Tech Jobs
  • Contact

Israeli Ministry of Health Clears a Path to Allow Per Patient Compassionate Use Treatment of Covid-19 Patients with Pluristem’s PLX Cells

March 17, 2020 By admin

HAIFA, Israel, March 17, 2020 — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today announced that the Israeli Ministry of Health has approved Pluristem’s request to seek approvals to treat COVID-19 coronavirus patients under the per-patient compassionate use framework in Israel. The Israeli Ministry of Health may approve proposed treatments on a per-patient basis for the use of PLX cell therapy including intra-muscular (IM) administration of PLX-PAD for the proposed treatment of severe pneumonia resulting from COVID-19 and preventing the deterioration of patients towards Acute Respiratory Distress Syndrome (ARDS) and sepsis. Pluristem has not yet submitted any such request for treatment of a specific COVID-19 patient, and there is no assurance that any such request will be approved by Israeli Ministry of Health.

Pluristem recently announced a collaborative agreement with the BIH Center for Regenerative Therapy (BCRT) and the Berlin Center for Advanced Therapies (BeCAT) at Charité University of Medicine Berlin to evaluate the therapeutic effects of PLX cell product candidates for the potential treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus.

“Pluristem is highly committed to use its technology, knowledge and expertise in order to attempt to provide a better outcome to patients infected by complications associated with COVID-19. We hope and believe that the ease of use of our PLX cell product candidates, and their being readily available, may play an important role in case there is a need to treat large numbers of patients with respiratory complications. Our collaborative research with Charité of Berlin on our PLX COVID-19 program enables us to accelerate the implementation of our cell therapies candidates towards this indication, as we continue our efforts to expand the program to additional countries,” stated Pluristem President and CEO Yaky Yanay.

PLX cells are available off-the-shelf and once commercialized, can be manufactured in large scale quantities, offering a key advantage in addressing a global pandemic. PLX cells are allogeneic mesenchymal-like cells that have immunomodulatory properties that induce the immune system’s natural regulatory T cells and M2 macrophages, and thus may prevent or reverse the dangerous overactivation of the immune system. Accordingly, PLX cells may potentially reduce the incidence and\or severity of COVID-19 pneumonia and pneumonitis leading hopefully to a better prognosis for the patients. Previous pre-clinical findings of PLX cells revealed therapeutic benefit in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal injury which are potential complications of the severe COVID-19 infection. Clinical data using PLX cells demonstrated the strong immunomodulatory potency of PLX cells in patients post major surgery. Taken together, PLX cells’ potential capabilities with the safety profile observed from clinical trials involving hundreds of patients worldwide potentially position them as a therapy for mitigating the tissue-damaging effects of COVID-19.

About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company’s proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.

Source: Pluristem Therapeutics, Inc.

Filed Under: Featured Posts Tagged With: coronavirus, Covid-19

Footer

Recent Posts

  • Haifa’s Real Estate: A Bubble on the Brink
  • The Proliferation of Ring-Necked Parakeets in Israel: A Complex Ecological Challenge
  • Voyantis Redefines Growth Strategy with $41M Funding Round Led by Intel Capital
  • A pogrom in the streets of Amsterdam
  • WITH ANTISEMITISM AT AN ALL-TIME HIGH, JUST AHEAD OF KRISTALLNACHT, IMMERSIVE XR EXPERIENCE LAUNCHES, GIVING VIEWERS UNPRECEDENTED LOOK INSIDE A PIVOTAL MOMENT IN THE HOLOCAUST
  • UN chief Antonio Guterres just now mourned a mass murderer who oversaw the kidnapping of Hersh Goldberg-Polin
  • Good Morning from Haifa!
  • Haifa’s Empty Beaches Amid Ongoing Conflict with Hezbollah
  • Gloryless Fall of Sinwar: From Hiding to Oblivion
  • Genetic study suggests that Columbus was Jewish

Media Partners

  • Cybersecurity Market
  • Media Partners
Inside the Industrialized Scam Economy: Arkose Labs Unveils How Digital Fraudsters Thrive
Barcelona Cybersecurity Congress Highlights Strategic Importance of Cybersecurity
Open Source, AI and Cybersecurity Converge in Amsterdam: Previewing the 2025 Open Source Summit Europe and AI_dev GenAI Summit
SquareX to Uncover Data Splicing Attacks at BSides San Francisco, A Major DLP Flaw that Compromises Data Security of Millions
Lattica Emerges from Stealth to Solve AI’s Biggest Privacy Challenge with FHE
Logicube’s Falcon®-NEO2 Forensic Imager Achieves Project VIC Validation; Now VICS Data Compliant
Cybersecurity Luminary Phil Venables Joins Ballistic Ventures as Venture Partner
ZeroRISC Secures $10M to Build Transparent, Secure Supply Chains
INE Security and RedTeam Hacker Academy Announce Partnership to Advance Cybersecurity Skills in the Middle East
Speaker Proposal Deadline Approaches for OpenSSL Conference 2025 in Prague
Israel News
Syndicator
Yellow Fiction
Domain Market Research
ESN
VPNW
Photography
Technology Conference
App Coding
Media Instances

Media Partners

  • Defense Market
  • Media Partners
EDGE Signs Historic $2.45 Billion Naval Contract with Kuwait
Oshkosh Defense Secures $208 Million Order for Joint Light Tactical Vehicles (JLTV)
goTenna awarded $15M AFWERX STRATFI SBIR Contract for Air Force CoTS Connectivity
United Launch Alliance Successfully Launches 100th National Security Mission
NATO Countries Bordering Russia Unite to Construct Advanced “Drone Wall” for Enhanced Security
Elbit Systems Awarded a $180 Million Contract From the Israeli MOD to Provide a new Mission Training Center for its F-16 Fleet
Lockheed Martin’s VISTA X-62A, a training aircraft, was flown by an AI agent for more than 17 hours
Navy Awards General Dynamics Bath Iron Works Contract for Three DDG 51 Destroyers
Germany Becomes Latest Country to Join the F-35 Lightning II Global Team
CACI to acquire Azure Summit Technology for $1.275 billion
Technology Conference
Bootstrapping
Agile Soft Dev
Media Instances
Renewability
Prints
Posters
Media Gallery
Opinion
OSINT

Copyright © 2015 IsraelNews.org

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT